131 related articles for article (PubMed ID: 7720819)
1. Specific lesions in the extrapyramidal system of the rat brain induced by 3-nitropropionic acid (3-NPA).
Pei G; Ebendal T
Exp Neurol; 1995 Mar; 132(1):105-15. PubMed ID: 7720819
[TBL] [Abstract][Full Text] [Related]
2. Chronic intranigral administration of brain-derived neurotrophic factor produces striatal dopaminergic hypofunction in unlesioned adult rats and fails to attenuate the decline of striatal dopaminergic function following medial forebrain bundle transection.
Lapchak PA; Beck KD; Araujo DM; Irwin I; Langston JW; Hefti F
Neuroscience; 1993 Apr; 53(3):639-50. PubMed ID: 8098137
[TBL] [Abstract][Full Text] [Related]
3. Quantitation of the levels of tyrosine hydroxylase and preproenkephalin mRNAs in nigrostriatal sites after 6-hydroxydopamine lesions.
Zhu YS; Jones SB; Burke RE; Franklin SO; Inturrisi CE
Life Sci; 1993; 52(19):1577-84. PubMed ID: 8097862
[TBL] [Abstract][Full Text] [Related]
4. Dopaminergic neurons in rat ventral midbrain express brain-derived neurotrophic factor and neurotrophin-3 mRNAs.
Seroogy KB; Lundgren KH; Tran TM; Guthrie KM; Isackson PJ; Gall CM
J Comp Neurol; 1994 Apr; 342(3):321-34. PubMed ID: 7912699
[TBL] [Abstract][Full Text] [Related]
5. Long-term induction of tyrosine hydroxylase expression: compensatory response to partial degeneration of the dopaminergic nigrostriatal system in the rat brain.
Blanchard V; Chritin M; Vyas S; Savasta M; Feuerstein C; Agid Y; Javoy-Agid F; Raisman-Vozari R
J Neurochem; 1995 Apr; 64(4):1669-79. PubMed ID: 7891094
[TBL] [Abstract][Full Text] [Related]
6. Intranigral ventral mesencephalic grafts and nigrostriatal injections of glial cell line-derived neurotrophic factor restore dopamine release in the striatum of 6-hydroxydopamine-lesioned rats.
Tang FI; Tien LT; Zhou FC; Hoffer BJ; Wang Y
Exp Brain Res; 1998 Apr; 119(3):287-96. PubMed ID: 9551829
[TBL] [Abstract][Full Text] [Related]
7. Glial cell line-derived neurotrophic factor (GDNF) gene delivery protects dopaminergic terminals from degeneration.
Connor B; Kozlowski DA; Unnerstall JR; Elsworth JD; Tillerson JL; Schallert T; Bohn MC
Exp Neurol; 2001 May; 169(1):83-95. PubMed ID: 11312561
[TBL] [Abstract][Full Text] [Related]
8. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine.
Przedborski S; Levivier M; Jiang H; Ferreira M; Jackson-Lewis V; Donaldson D; Togasaki DM
Neuroscience; 1995 Aug; 67(3):631-47. PubMed ID: 7675192
[TBL] [Abstract][Full Text] [Related]
9. Nociceptin/orphanin FQ and opioid receptor-like receptor mRNA expression in dopamine systems.
Norton CS; Neal CR; Kumar S; Akil H; Watson SJ
J Comp Neurol; 2002 Mar; 444(4):358-68. PubMed ID: 11891648
[TBL] [Abstract][Full Text] [Related]
10. Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long-lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer.
Georgievska B; Kirik D; Björklund A
Exp Neurol; 2002 Oct; 177(2):461-74. PubMed ID: 12429192
[TBL] [Abstract][Full Text] [Related]
11. The antioxidant drink effective microorganism-X (EM-X) pre-treatment attenuates the loss of nigrostriatal dopaminergic neurons in 6-hydroxydopamine-lesion rat model of Parkinson's disease.
Datla KP; Bennett RD; Zbarsky V; Ke B; Liang YF; Higa T; Bahorun T; Aruoma OI; Dexter DT
J Pharm Pharmacol; 2004 May; 56(5):649-54. PubMed ID: 15142343
[TBL] [Abstract][Full Text] [Related]
12. Glial cell line-derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6-hydroxydopamine-lesioned adult rats: comparison of intraventricular and intranigral delivery.
Lapchak PA; Miller PJ; Collins F; Jiao S
Neuroscience; 1997 May; 78(1):61-72. PubMed ID: 9135089
[TBL] [Abstract][Full Text] [Related]
13. Intrastriatal implantation of interleukin-1. Reduction of parkinsonism in rats by enhancing neuronal sprouting from residual dopaminergic neurons in the ventral tegmental area of the midbrain.
Wang J; Bankiewicz KS; Plunkett RJ; Oldfield EH
J Neurosurg; 1994 Mar; 80(3):484-90. PubMed ID: 7906726
[TBL] [Abstract][Full Text] [Related]
14. Haloperidol induces persistent down-regulation of tyrosine hydroxylase immunoreactivity in substantia nigra but not ventral tegmental area in the rat.
Levinson AJ; Garside S; Rosebush PI; Mazurek MF
Neuroscience; 1998 May; 84(1):201-11. PubMed ID: 9522374
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of brain-derived neurotrophic factor and neurotrophin-3 on neurochemical and behavioral deficits associated with partial nigrostriatal dopamine lesions.
Altar CA; Boylan CB; Fritsche M; Jones BE; Jackson C; Wiegand SJ; Lindsay RM; Hyman C
J Neurochem; 1994 Sep; 63(3):1021-32. PubMed ID: 7519657
[TBL] [Abstract][Full Text] [Related]
16. Alterations in tyrosine hydroxylase expression following partial lesions of the nigrostriatal bundle.
Sherman TG; Moody CA
Brain Res Mol Brain Res; 1995 Apr; 29(2):285-96. PubMed ID: 7609616
[TBL] [Abstract][Full Text] [Related]
17. Adrenalectomy counteracts the local modulation of astroglial fibroblast growth factor system without interfering with the pattern of 6-OHDA-induced dopamine degeneration in regions of the ventral midbrain.
Chadi G; Silva C; Maximino JR; Fuxe K; da Silva GO
Brain Res; 2008 Jan; 1190():23-38. PubMed ID: 18086466
[TBL] [Abstract][Full Text] [Related]
18. Glial cell line-derived neurotrophic factor prevents death, but not reductions in tyrosine hydroxylase, of injured nigrostriatal neurons in adult rats.
Lu X; Hagg T
J Comp Neurol; 1997 Nov; 388(3):484-94. PubMed ID: 9368855
[TBL] [Abstract][Full Text] [Related]
19. Altered melatonin MT
Kang NH; Carriere CH; Bahna SG; Niles LP
Brain Res; 2016 Dec; 1652():89-96. PubMed ID: 27693415
[TBL] [Abstract][Full Text] [Related]
20. Cyclosporin A attenuates the decrease in tyrosine hydroxylase immunoreactivity in nigrostriatal dopaminergic neurons and in striatal dopamine content in rats with intrastriatal injection of 6-hydroxydopamine.
Matsuura K; Makino H; Ogawa N
Exp Neurol; 1997 Aug; 146(2):526-35. PubMed ID: 9270064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
